Not recommended as a standalone test. If using serology testing, IgM combined with IgG is preferred. Do not use for diagnosis in immunocompromised individuals. Preferred test for detecting CMV infection is quantitative PCR (0051813
Semi-Quantitative Chemiluminescent Immunoassay
This test is New York DOH approved.
- Patient Preparation
- Serum separator tube. Also acceptable: Serum from umbilical cord blood.
- Specimen Preparation
- Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL) Acute and convalescent specimens must be labeled as such; parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as "acute" or "convalescent."
- Storage/Transport Temperature
- Unacceptable Conditions
- Plasma or urine. Contaminated, heat-inactivated or hemolyzed specimens.
- After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
|29.9 AU/mL or less:
||Indeterminate - Repeat testing in 10-14 days may be helpful.
|35.0 AU/mL or greater:
||Detected - IgM antibody to CMV detected, which may indicate a current or recent infection. However, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection.
CMV serology is not useful for the evaluation of active or reactivated infection in immunocompromised patients. Molecular diagnostic tests (i.e., PCR) are preferred in these cases.
This test should not be used for blood donor screening, associated re-entry protocols, or for screening Human Cell, Tissues and Cellular and Tissue-Based Products (HCT/P).
|Component Test Code*||Component Chart Name|
|0050553||CMV Antibody IgM|
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at email@example.com.